Zydus' Oxcarbazepine Tablets Receive Final Approval from USFDA

Zydus Lifesciences Limited declared on Tuesday that it had received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP in 150 mg, 300 mg, and 600 mg strengths. These tablets, equivalent to the US Reference Listed Drug (RLD) Trileptal Tablets, are used to treat seizure disorders, including epilepsy. Zydus will manufacture the drugs at its formulation manufacturing facility in Baddi, Himachal Pradesh, India.


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks